Catalyst Funds Management
WHWK icon

Catalyst Funds Management’s Whitehawk Therapeutics WHWK Stock Holding History

Catalyst Funds Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,011
Closed -$93.2K – 932
2026
Q1 		$93.2K Buy
+27,011
New +$84.6K 0.02% 493
2024
Q4 		– Sell
-4,100
Closed -$8.45K – 1331
2024
Q3 		$8.45K Hold
4,100
– – ﹤0.01% 1207
2024
Q2 		$5.99K Buy
+4,100
New +$7.6K ﹤0.01% 1030

Other funds holding WHWK

YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
QVT Financial
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Catalyst Funds Management's WHWK Position: Q2 2026 in Review

Catalyst Funds Management sold out of Whitehawk Therapeutics (WHWK) in Q2 2026, closing a stake of 27,011 shares — an estimated $93.2K sold.

Catalyst Funds Management first reported a position in WHWK in Q2 2024 and held it in 3 quarters. The position peaked at $93.2K in Q1 2026. 77 funds tracked by Wall St. Rank hold WHWK as of Q2 2026.

  • Catalyst Funds Management reported no remaining Whitehawk Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 27,011 Whitehawk Therapeutics shares in Q2 2026, an estimated $93.2K.
  • Catalyst Funds Management first reported a position in Whitehawk Therapeutics in Q2 2024 and held it in 3 quarters.
  • Catalyst Funds Management's Whitehawk Therapeutics position peaked at $93.2K in Q1 2026.
  • 77 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.